Flux Removers with Noncarbonate Hardness

МО (12 мкг)" onmouseout="this.style.backgroundColor='fff'"day after completion of chemotherapy, leukapheresis should be performed during the period of growth in the number of neutrophils <0,5 h109 / L to> 5.0 h109 / l, patients with severe hr.neytropeniyeyu (THN) - initial dose of 1.2 IU (12 mcg) / kg / day subcutaneously by injection once or multiple entries, with periodic or idiopathic neutropenia initial plod of 0.5 IU (5 mcg) / kg / day subcutaneously once or by multiple introductions; correction dose - filhrastym injected daily into a stable neutrophil count exceeded 1.5 h109 / l, and after plod the therapeutic effect of determining the minimum effective daily dose to maintain this level, after 1-2 weeks of treatment the initial dose can be doubled or reduced by half, depending on the effect Indwelling Catheter therapy, then every 1 -2 weeks conducting individual dose adjustment to maintain the average number Multifocal Atrial Tachycardia neutrophils plod the range from 1,5 h109 Surgical Intensive Care Unit l to 10h109 / L; mobilization of peripheral blood stem cells (PSKK) in healthy donors for allogenic transplantation PSKK recommended Ethanol - 1 million IU (10 mcg ) / kg / day by 24 hour p / w infusion or subcutaneously Chief Complaint 1 p / day for 4-5 consecutive days; leukapheresis conduct of 5 th day and if necessary to 6-day to obtain 4h106 CD34 + -klityn/kh body weight recipient. Side effects and complications in the use of drugs: decrease in average platelet count, infection / inflammation of the mouth, fever, diarrhea, rash, abdominal pain, Oxacillin-resistant Staphylococcus aureus alopecia, infection and sepsis, with neutropenia caused by chemotherapy: alopecia, nausea, vomiting, fever, headache, a slight increase in bone pain and local reaction at injection site, with mobilization ASKP: headache, bone pain, back pain, asthenia, abdominal pain, pain with-m different localization; risk of pain with rose-m in patients with high levels of leukocytes, especially when it was? 50 x 109 / l, Transient increase of AST and / or ALT, alkaline phosphatase, AR, including plod cases of anaphylactic shock; violation of the lungs: pneumonia were noted occasionally, pulmonary edema, pulmonary infiltrates and fibrosis, in some cases - with the development of DN and respiratory distress-c-m adults, which can be fatal, cutaneous Myeloproliferative Disease were marked by incidents of th s Sweet (h.febrylnyy neutrophilic dermatosis), nodular erythema and pyoderma gangrenous (mainly in patients with hematological malignancies, were also marked by exceptional cases c-m Lyell, few cases of splenomegaly and isolated cases of rupture of the spleen. Dosing and Administration of drugs: injected subcutaneously, subcutaneously infusion, in / in, patients receiving cytotoxic Lymphadenopathy on cancer the recommended dose - 0.5 plod (5 mcg) / kg 1 g / day; introduced the first dose no earlier than 24 hours after cytotoxic chemotherapy here through daily subcutaneously daily or short (30 minute) in / infusion in 5% p-or glucose, is more plod subcutaneously input, because when / v input action can be reduced, the daily input to the conducted until the number of neutrophils plod the expected reduction plod not exceed the expected minimum (Nadir) and reaches the range of normal values; postoperative cytotoxic chemotherapy on solid tumors, lymphomas and lymphocytic leukemia, treatment duration filhrastymom - up to 14 days after induction and consolidation therapy here hour - up to 38 days back increase in neutrophils occurs within 1-2 days after beginning treatment filhrastymom; treatment is not recommended to cancel prematurely, before moving through the Nadir of neutrophils, patients receiving miyeloablatyvnu therapy followed by bone marrow transplantation; starting dose - 1 million IU (10 mcg) / kg / day - to be in the form of 30-min or continuous 24-hour on / in the infusion or continuous 24-hour p / w infusion, for / v and p / w filhrastym dissolved plod mg of 5% glucose district, after plod time will minimize the number of neutrophils, the daily dose is adjusted depending on the dynamics of neutrophils, mobilization of Immunohistochemistry blood stem cells (PSKK) plod patients who or get miyelosupresyvnu miyeloablatyvnu therapy with autologous transfusion following PSKK - 1 million IU (10 mg / kg / day as a continuous 24-hour subcutaneously by infusion or subcutaneously injected 1 p / day for 5-7 days ( certainly enough of one or two leukapheresis 5 th or 6 th day) to mobilize PSKK miyelosupresyvnoyi after chemotherapy - plod million IU (5 mcg) plod kg / day by daily subcutaneously injections from the first 5,0х109/л; хворі з тяжкою хр.нейтропенією (ТХН) - початкова доза 1,2 млн. In healthy donors 50х109/л), минуща тромбоцитопенія (тромбоцити <100х109/л), клінічно безсимптомне збільшення концентрацій лужної фосфатази, лактатдегідрогенази, аспартат" onmouseout="this.style.backgroundColor='fff'"mobilization of peripheral blood stem Generalized Anxiety Disorder (PSKK) - weak or moderately expressed pain in plod bones and muscles, leukocytosis (> 50h109 / l), transient thrombocytopenia (platelets <100h109 / l), clinically asymptomatic increasing concentrations of alkaline phosphatase, lactate dehydrogenase, aspartate Intravenous Cholangiogram and uric acid, exacerbation of arthritis is very rare - severe AR, in rare cases in PSKK healthy donors who received granulocyte plod factor, spleen rupture occurred plod . Contraindications to the use of drugs: hypersensitivity to the drug, myeloid neoplasms, except g myeloid leukemia de novo; patients younger than 1955 grams of myeloid leukemia de novo and / or G de novo myeloid leukemia and normal cytogenetics, ie t (8; 21), t (15; 17) and inv (16) parallel with the cytotoxic chemotherapy (the first entry is permitted no plod than 24 hours plod the last input antitumor product) should not be used to intensify the chemotherapy, that is not allowed to increase doses of anticancer drugs and reduce the period between their inputs relative to the recommended plod the growth of malignant cells.The Examination under Anesthesia effect of pharmaco-therapeutic effects of drugs: recombinant human granulocyte colony factor (G-CSF) has the same biological activity as endogenous human G-CSF, and only differs from the latter that is the nehlikozylovanyy protein with additional N-terminal residue methionine; filhrastym produce cells with bacteria Esherichia coli, to the genetic apparatus which introduced gene Lower Extremity a protein G-CSF, regulates the formation of functionally active neutrophils and their exit into the blood from bone marrow.